C. Soh

Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).

Fairooz F. Kabbinavar, V.A. Miller, B. E. Johnson et al. · Journal of Clinical Oncology · 2010 · 110 citations

Cancer Management, Pathology, First-line Treatment +17

Validation of the Western Ontario and McMaster University Osteoarthritis Index in Asians with Osteoarthritis in Singapore

Julian Thumboo, Ling-Huo Chew, C. Soh · Osteoarthritis and Cartilage · 2001 · 106 citations · Full text

Global Health, Chronic Musculoskeletal Condition, Osteoarthritis +5

A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

V. A. Miller, Paula G. O’Connor, C. Soh et al. · Journal of Clinical Oncology · 2009 · 67 citations

Cancer Management, First-line Treatment, Pharmacotherapy +19

Interpretation of the Tuberculin Skin Test in <i>Mycobacterium bovis</i> BCG-vaccinated Singaporean Schoolchildren

Cynthia Bin Eng Chee, C. Soh, Irving Charles Boudville et al. · American Journal of Respiratory and Critical Care Medicine · 2001 · 59 citations

Measuring Health-related Quality of Life in Singapore: Normal Values for the English and Chinese SF-36 Health Survey

Julian Thumboo, S P Chan, David Machin et al. · Annals of the Academy of Medicine Singapore · 2002 · 43 citations